Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.

Seetharaman Balasenthil1, Ying Huang2, Suyu Liu3

  • 1Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Journal of the National Cancer Institute
|April 5, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting median survival from early follow-up data: opportunities, limitations, and extensions.

Journal of the National Cancer Institute·2026
Same author

LLM-Driven Extraction of NI-RADS and Imaging Tumor Characteristics to Enhance Oropharyngeal Cancer Survivorship Surveillance.

medRxiv : the preprint server for health sciences·2026
Same author

Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study.

Cancer letters·2026
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Sex differences in nerve injury-induced neuropathic pain via REST in primary sensory neurons.

Neurobiology of pain (Cambridge, Mass.)·2026

A new biomarker panel combining tissue factor pathway inhibitor (TFPI) and tenascin C (TNC-FN III-C) with CA 19-9 shows promise for early pancreatic cancer detection. This panel improves upon CA 19-9 alone, aiding in identifying surgically resectable disease.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Cancer Diagnostics

Background:

  • Early detection of pancreatic ductal adenocarcinoma (PDAC) is critical due to the lack of sensitive and specific biomarkers.
  • Current standard biomarker CA 19-9 lacks sufficient predictive value for population-based screening.

Purpose of the Study:

  • To validate a novel functional genomics-based plasma migration signature biomarker panel.
  • To assess the diagnostic performance of TFPI, TNC-FN III-C, and CA 19-9 in early-stage PDAC detection.

Main Methods:

  • Plasma levels of TFPI, TNC-FN III-C, and CA 19-9 were measured using ELISA in three early-stage PDAC cohorts.
  • Logistic regression models combined biomarkers to classify patients and controls, with adjustments for age and diabetes.
  • Performance was evaluated in independent validation cohorts and sub-populations without diabetes or pancreatitis.

Related Experiment Videos

Main Results:

  • The TFPI/TNC-FN III-C/CA 19-9 panel significantly improved CA 19-9's performance in detecting early-stage PDAC across cohorts.
  • High diagnostic accuracy (AUCs ranging from 0.83 to 0.92) was observed for discriminating early PDAC from healthy controls.
  • In subcohorts without diabetes or pancreatitis, the panel demonstrated potential clinical utility for early detection (AUCs up to 0.93).

Conclusions:

  • The TFPI/TNC-FN III-C migration signature significantly enhances the predictive power of CA 19-9 for early-stage PDAC detection.
  • This panel holds potential clinical utility for identifying surgically resectable PDAC, contributing to improved patient survival.
  • Further validation may establish this panel as a valuable tool in the fight against pancreatic cancer.